Pat Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared a post on X by SHINE Technologies, adding:
“I see the amazing revolution of PRECISION tumor-targeted radio therapy with these cancer fighting isotopes manufactured by Shine. This will replace tissue damaging current radiation therapy . The field of antibody and peptide radio-isotope oncology is about to explode …but to protect the ALC count ( drop in NK and T cells from the radiation) we will need a solution!
Guess what does that? Thank goodness there is one. IL-15 ..a T and NK cell growth factor to the rescue! ALC matters. Pluvicto and IL15 combo trial being planned. Unstoppable as the world of cancer therapy transforms to biologics.”
Quoting SHINE Technologies:
“We’re producing cancer-fighting isotopes, imaging and testing critical aerospace components, enabling next-gen fusion research and building toward clean energy. Want to see where it all happens?”